CCXI [NASD]
ChemoCentryx, Inc.
Index- P/E- EPS (ttm)-2.00 Insider Own4.10% Shs Outstand70.83M Perf Week26.50%
Market Cap1.34B Forward P/E- EPS next Y-0.74 Insider Trans-1.40% Shs Float61.25M Perf Month-1.60%
Income-140.70M PEG- EPS next Q-0.48 Inst Own76.20% Short Float9.79% Perf Quarter-33.76%
Sales27.30M P/S49.23 EPS this Y-123.80% Inst Trans1.19% Short Ratio4.07 Perf Half Y-45.97%
Book/sh3.65 P/B5.72 EPS next Y-15.20% ROA-31.50% Target Price76.57 Perf Year109.44%
Cash/sh5.29 P/C3.95 EPS next 5Y- ROE-47.20% 52W Range9.53 - 42.16 Perf YTD-42.71%
Dividend- P/FCF- EPS past 5Y-17.00% ROI-41.90% 52W High-47.39% Beta1.96
Dividend %- Quick Ratio5.10 Sales past 5Y22.00% Gross Margin98.10% 52W Low132.74% ATR1.67
Employees178 Current Ratio5.10 Sales Q/Q-47.10% Oper. Margin- RSI (14)59.12 Volatility8.56% 8.83%
OptionableYes Debt/Eq0.09 EPS Q/Q-27.70% Profit Margin- Rel Volume1.66 Prev Close20.86
ShortableYes LT Debt/Eq0.02 EarningsMay 05 AMC Payout- Avg Volume1.47M Price22.18
Recom1.60 SMA2020.40% SMA502.48% SMA200-16.36% Volume855,464 Change6.33%
Oct-11-21Upgrade SVB Leerink Mkt Perform → Outperform $64
Oct-11-21Upgrade JP Morgan Underweight → Neutral $14 → $38
Oct-08-21Upgrade Raymond James Outperform → Strong Buy $62 → $107
Oct-08-21Upgrade Piper Sandler Neutral → Overweight
Jul-07-21Upgrade Stifel Hold → Buy $26 → $31
May-07-21Downgrade SVB Leerink Outperform → Mkt Perform
May-07-21Downgrade Stifel Buy → Hold $93 → $26
May-07-21Downgrade Raymond James Strong Buy → Outperform
May-07-21Downgrade Piper Sandler Overweight → Neutral $80 → $25
May-07-21Downgrade JP Morgan Neutral → Underweight $57 → $17
Mar-02-21Reiterated H.C. Wainwright Buy $83 → $101
Mar-02-21Initiated Stifel Buy $93
Oct-29-20Downgrade JP Morgan Overweight → Neutral $63 → $60
Jun-17-20Initiated BTIG Research Buy $70
May-27-20Initiated Wells Fargo Overweight $79
May-12-20Reiterated H.C. Wainwright Buy $60 → $69
Jan-24-20Reiterated H.C. Wainwright Buy $40 → $60
Nov-26-19Reiterated Piper Jaffray Overweight $17 → $54
Nov-26-19Reiterated H.C. Wainwright Buy $23 → $40
Mar-27-19Upgrade B. Riley FBR Neutral → Buy $12.50 → $22
May-18-22 08:30AM  
May-16-22 08:30AM  
May-11-22 08:30AM  
May-06-22 03:38PM  
May-05-22 06:35PM  
04:05PM  
Apr-28-22 03:02PM  
08:30AM  
Apr-19-22 09:13AM  
Apr-13-22 08:30AM  
Mar-31-22 11:30AM  
Mar-30-22 11:30AM  
Mar-07-22 08:43AM  
Mar-05-22 06:08AM  
Mar-02-22 01:51PM  
10:33AM  
Mar-01-22 05:35PM  
04:05PM  
Feb-23-22 08:30AM  
Feb-09-22 08:30AM  
Feb-08-22 03:25PM  
Feb-04-22 09:38AM  
Jan-20-22 11:31AM  
Jan-19-22 10:47AM  
08:30AM  
Jan-18-22 08:22PM  
Jan-12-22 10:30AM  
Jan-07-22 05:22AM  
Jan-04-22 08:30AM  
Jan-03-22 06:04AM  
Dec-27-21 07:19AM  
Nov-23-21 05:18AM  
Nov-15-21 11:12AM  
Nov-12-21 08:30AM  
Nov-10-21 10:44AM  
08:00AM  
06:20AM  
01:01AM  
Nov-09-21 05:55PM  
04:05PM  
Nov-08-21 09:29AM  
Nov-04-21 08:30AM  
Nov-02-21 08:30AM  
Nov-01-21 03:01PM  
Oct-14-21 07:18AM  
Oct-13-21 10:00AM  
Oct-11-21 07:43PM  
08:38AM  
08:30AM  
04:21AM  
02:27AM  
Oct-09-21 09:19AM  
Oct-08-21 05:57PM  
05:40PM  
04:26PM  
02:50PM  
02:36PM  
01:10PM  
12:53PM  
12:20PM  
12:05PM  
12:03PM  
08:24AM  
08:04AM  
07:28AM  
07:22AM  
07:04AM  
07:00AM  
Sep-27-21 08:30AM  
Sep-21-21 01:10PM  
Sep-20-21 02:06AM  
Sep-16-21 09:11AM  
Sep-15-21 09:47AM  
Sep-08-21 11:30AM  
Sep-02-21 08:30AM  
Aug-11-21 08:27AM  
01:29AM  
Aug-10-21 10:54AM  
08:01AM  
Aug-09-21 05:55PM  
04:05PM  
Aug-06-21 01:54PM  
Aug-04-21 08:30AM  
Aug-02-21 03:01PM  
08:30AM  
Jul-27-21 06:13AM  
Jul-21-21 04:24AM  
Jul-10-21 06:44AM  
Jul-09-21 04:31PM  
Jul-08-21 02:25AM  
Jul-07-21 11:14PM  
09:30AM  
08:21AM  
Jul-06-21 03:21PM  
02:35PM  
10:03AM  
10:00AM  
09:47AM  
09:17AM  
08:30AM  
ChemoCentryx, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of new medications for inflammatory disorders, autoimmune diseases, and cancer in the United States. It develops Avacopan, an orally administered selective complement 5a receptor inhibitor for the treatment of anti-neutrophil cytoplasmic autoantibody-associated vasculitis; and completed Phase II clinical trial for the treatment of patients with severe hidradenitis suppurativa, as well as patients with complement 3 glomerulopathy. The company is also developing CCX559, an orally-administered inhibitor for programmed death protein 1/programmed death-ligand 1 for the treatment of various cancers; and CCX507, an orally-administered inhibitor of the chemokine receptor CC9, which has completed Phase I clinical trial or the treatment of inflammatory bowel disease. In addition, it develops CCX587 for the treatment of TH17 driven diseases. ChemoCentryx, Inc. was incorporated in 1996 and is headquartered in San Carlos, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Parker Geoffrey M.DirectorMay 02Option Exercise14.4212,500180,250124,413May 03 10:29 AM
Jain RitaEVP, Chief Medical OfficerMar 27Option Exercise0.005,251028,137Mar 29 07:50 PM
FECZKO JOSEPH MDirectorJan 21Option Exercise15.4137,500577,750148,127Jan 25 08:03 PM
Schall Thomas J.President and CEOJan 01Option Exercise0.0084,23402,439,050Jan 04 09:42 PM
KANAYA SUSAN MEVP, CFO and Sec.Jan 01Option Exercise0.0030,7990149,564Jan 04 09:38 PM
Cappel Markus J.Chief Bus. Officer & TreasurerJan 01Option Exercise0.0020,9340106,760Jan 04 09:35 PM
Tyree James LDirectorDec 17Option Exercise13.2237,500495,75052,775Dec 21 06:33 PM
Tyree James LDirectorDec 17Sale35.0237,5001,313,16515,275Dec 21 06:33 PM
Schall Thomas J.President and CEODec 01Option Exercise10.8845,936499,9942,354,816Dec 03 07:39 PM
Vifor (International) Ltd10% OwnerOct 12Sale39.434,000,000157,720,0005,194,085Oct 13 07:05 PM
Tyree James LDirectorMay 21Option Exercise0.004,660017,729May 24 08:19 PM
Parker Geoffrey M.DirectorMay 21Option Exercise0.004,660013,350May 24 08:09 PM
Jain RitaDirectorMay 21Option Exercise0.004,660022,886May 24 07:55 PM
Tyree James LDirectorMay 21Sale9.762,45423,95615,275May 24 08:19 PM